Fertility Treatments Market Report 2026

The fertility treatments market size has grown strongly in recent years. It will grow from $19.52 billion in 2025 to $21.29 billion in 2026 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to growth in infertility rates, availability of fertility drugs, expansion of ivf infrastructure, improved reproductive diagnostics, increasing healthcare access.

The fertility treatments market size is expected to see strong growth in the next few years. It will grow to $29.7 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to advancements in fertility drug development, expansion of personalized treatment protocols, rising demand for minimally invasive fertility procedures, increasing fertility awareness, growth in fertility tourism. Major trends in the forecast period include rising adoption of advanced fertility treatment techniques, increased use of hormonal and ovulation induction drugs, expansion of assisted reproductive technology centers, growing demand for male and female infertility treatments, integration of ai in treatment planning.

The declining fertility rate is expected to support the expansion of the fertility treatments market in the coming years. A decline in fertility refers to a reduced ability of individuals or couples to conceive and have biological children, often influenced by factors such as advancing age, underlying medical conditions, lifestyle factors, or environmental exposures. Fertility treatments help address infertility challenges through medical interventions such as intrauterine insemination (IUI) and in vitro fertilization (IVF), thereby improving the likelihood of conception for those experiencing reduced fertility. For example, in April 2023, the World Health Organization (WHO), a Switzerland-based United Nations specialized agency for global public health, reported that approximately 17.5% of the global adult population - around one in six individuals - are affected by infertility. Therefore, rising infertility rates are driving growth in the fertility treatments market.

Leading companies in the fertility treatments market are increasingly concentrating on the development of innovative IVF solutions, such as iPSC-derived ovarian support cell (OSC)-based in vitro maturation (IVM), to strengthen their competitive position. This advanced approach utilizes laboratory-engineered support cells derived from induced pluripotent stem cells to replicate the natural ovarian environment and enable egg maturation outside the body. For instance, in December 2024, Gameto, a US-based biotechnology company, announced the world’s first live birth achieved using Fertilo, its OSC-IVM technology. Fertilo eliminates approximately 80% of hormonal injections, reduces treatment duration from 10-14 days to about three days, and lowers risks such as ovarian hyperstimulation syndrome. Although this innovation offers a faster, safer, and more accessible fertility treatment option, regulatory considerations and long-term safety assessments remain important challenges.

In January 2024, IVI RMA Global, a Spain-based provider of assisted reproductive medicine and fertility clinic services, acquired the North American operations of Eugin Group, including Boston IVF and Trio Fertility, for an undisclosed sum. Through this acquisition, IVI RMA Global expanded its presence in the US and Canadian fertility markets, significantly strengthening its global clinic network and reaffirming its commitment to delivering evidence-based fertility services to a wider patient population. Eugin Group is a Spain-based, established provider of fertility and assisted reproductive services, operating networks of IVF clinics and reproductive medicine solutions across North America under the Boston IVF and Trio brands.

Major companies operating in the fertility treatments market are Apollo Hospitals Enterprise Ltd., Care Fertility Group Limited, Genea Limited, Johns Hopkins Health System Corp., Medicover AB, Monash IVF Group, Progyny Inc., Vitrolife AB, Carolinas Fertility Institute PLLC, OvaScience Inc., Xytex Cryo International Ltd., Merck Group, Cook Group Incorporated, CooperSurgical Inc., Instituto Bernabeu, INVO Bioscience Inc., Cooper Companies Inc., Virtus Health Ltd., CryoChoice LLC, FUJIFILM Irvine Scientific Inc., LABOTECT GMBH, Fertility Focus Limited, Olympus Corporation, Irvine Scientific sales Company Inc., Ferring Pharmaceuticals Inc., Prelude Fertility Inc., Boston IVF, RMA Fertility Clinics, Shady Grove Fertility, CCRM Management Company LLC, IVIRMA Global, CARE Fertility.

North America was the largest region in the fertility treatment market in 2025. Western Europe was the second largest region in the fertility treatment market. The regions covered in the fertility treatments market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the fertility treatments market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the fertility treatments market by raising costs for imported IVF equipment, laboratory reagents, cryopreservation systems, and diagnostic devices. Fertility clinics and hospitals in Asia-Pacific and Latin America are most affected due to reliance on international suppliers. These cost pressures can slow expansion of fertility treatment services. However, tariffs are encouraging domestic manufacturing of fertility equipment and reagents, strengthening long-term market resilience.

The fertility treatments market research report is one of a series of new reports that provides fertility treatments market statistics, including fertility treatments industry global market size, regional shares, competitors with a fertility treatments market share, detailed fertility treatments market segments, market trends and opportunities, and any further data you may need to thrive in the fertility treatments industry. This fertility treatments market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Fertility treatment refers to medical care provided to men or women to enhance their chances of conceiving a child. It is used in the management of infertility and often involves hormone therapies and ovulation-supporting medications, sometimes combined with minor surgical procedures.

The main product types used in fertility treatment include reagents and equipment. Reagents are substances or compounds added to a system to trigger a chemical reaction or to detect whether a reaction has taken place. These treatments are carried out for both female and male patients in fertility clinics, hospitals, surgical centers, and clinical research institutes.

The fertility treatment market includes revenues earned by entities by providing medicinal services, surgical services, and assisted services such as in vitro fertilization. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.